Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
Key takeaways
- Is Anaptys Bio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
- Ultimately, Piper Sandler stated that it believes the separation makes sense, as it effectively works to protect and optimize the value of the royalty business.
- In another development, AnaptysBio, Inc.
Is Anaptys Bio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026? Noor Ul Ain Rehman Mon, May 11, 2026 at 6:13 AM GMT+7 1 min read ANAB TRAX VNDA Anaptys Bio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on Anaptys Bio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks Biotherapeutics (TRAX) spinoff, and thus now operates as a royalty management company, exclusively responsible for its financial collaborations with GSK and Vanda Pharmaceuticals.
Ultimately, Piper Sandler stated that it believes the separation makes sense, as it effectively works to protect and optimize the value of the royalty business. This is fundamentally distinct from the biopharma development company.
In another development, AnaptysBio, Inc. (NASDAQ:ANAB) announced on April 24 that the Delaware Chancery Court has dismissed Tesaro’s anticipatory breach of contract claim against the company, with the ruling agreeing with Anaptys’ position that it has never repudiated the Collaboration and Exclusive License Agreement with Tesaro regarding the development and commercialization of Jemperli. Tesaro is a subsidiary of GSK.